Silence Therapeutics plc Research and Development Expense
Silence Therapeutics plc (SLNCF) reported Research and Development Expense of $9.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Silence Therapeutics plc research and development expense for the quarter ending 2026-06-30 was $9.15M, a 48.16% decline year-over-year.
- Silence Therapeutics plc research and development expense for the quarter ending 2026-03-31 was $9.12M, a 56.17% decline year-over-year.
- Silence Therapeutics plc research and development expense for the quarter ending 2025-12-31 was $8.75M, a 60.37% decline year-over-year.
- Silence Therapeutics plc research and development expense for the quarter ending 2025-09-30 was $20.54M, a 1.91% increase year-over-year.
- Silence Therapeutics plc research and development expense for fiscal 2025 was $67.75M, a 0.19% decline from fiscal 2024.
- Silence Therapeutics plc research and development expense for fiscal 2024 was $67.88M, a 19.22% increase from fiscal 2023.
- Silence Therapeutics plc research and development expense for fiscal 2023 was $56.94M, a 30.74% increase from fiscal 2022.
- Silence Therapeutics plc research and development expense for fiscal 2022 was $43.55M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.15M 10-Q · filed 2026-08-10 | $18.27M 10-Q · filed 2026-08-10 | $27.02M derived: sum of 3 quarters · filed 2026-08-10 | $47.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $9.12M 10-Q · filed 2026-05-07 | $17.87M derived: sum of 2 quarters · filed 2026-05-07 | $38.41M derived: sum of 3 quarters · filed 2026-05-07 | $56.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $29.29M derived: sum of 2 quarters · filed 2026-03-05 | $46.94M derived: sum of 3 quarters · filed 2026-08-10 | $67.75M 10-K · filed 2026-03-05 |
| 2025-09-30 | $20.54M 10-Q · filed 2025-11-06 | $38.19M derived: sum of 2 quarters · filed 2026-08-10 | $59.00M 10-Q · filed 2025-11-06 | $81.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $17.65M 10-Q · filed 2026-08-10 | $38.46M 10-Q · filed 2026-08-10 | $60.54M derived: sum of 3 quarters · filed 2026-08-10 | $80.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $20.81M 10-Q · filed 2026-05-07 | $42.89M derived: sum of 2 quarters · filed 2026-05-07 | $63.05M derived: sum of 3 quarters · filed 2026-05-07 | $76.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $42.24M derived: sum of 2 quarters · filed 2026-03-05 | $56.04M derived: sum of 3 quarters · filed 2026-03-05 | $67.88M 10-K · filed 2026-03-05 |
| 2024-09-30 | $20.16M 10-Q · filed 2025-11-06 | $33.96M derived: sum of 2 quarters · filed 2025-11-06 | $45.81M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $13.80M 10-Q · filed 2025-08-07 | $25.65M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $11.85M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $56.94M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $43.55M 10-K · filed 2025-02-27 |